Read time: 2 minutes.
Historically, approaches to treating lung cancer included surgery, radiation, and chemotherapy. The past decade ushered in a new era of treatments with targeted therapy and immunotherapy. Now, we are seeing the emergence of another class of lung cancer treatments called antibody-drug conjugates (ADCs), that are a combination of targeted therapy and chemotherapy.
ADCs act like a “smart chemotherapy” that aim to deliver the drug compound directly to cancer cells, reducing harm to healthy tissue.
As part of LUNGevity’s International Lung Cancer Survivorship Conference last September, we hosted an educational session about ADCs with Benjamin Levy, MD, of Johns Hopkins Sidney Kimmel Cancer Center and Amy Moore, PhD, of LUNGevity Foundation. In the video below, Dr. Levy explains what ADCs are and why they are exciting for the lung cancer community.
Many studies are underway to evaluate the use of ADCs in treating different types of lung cancer.
Sign up here to be notified when registration opens for the 2025 International Lung Cancer Survivorship Conference.
Introductions: 00:00–1:20
Learn more about the presenters and enjoy some fun baseball analogies as they go through the introductions.
Antibody-Drug Conjugate (ADC) Basics: 1:21–12:08
Join Dr. Levy as he lays the foundation for antibody-drug conjugates (ADCs), explaining what they are and how they work.
Treating HER2+ Lung Cancer with ADCs: 12:09–17:24
Learn about the history of ADCs in lung cancer, starting with the effective treatment of tumors with HER2 biomarkers. Don’t miss the incredible scans demonstrating the strong benefit from ADC therapy.
Brain Metastasis and ADCs: 17:25–19:19
Many of the researchers were surprised to see that ADCs showed promising effects in reducing brain metastasis. Learn more about treating brain metastasis with ADCs in this section.
ADCs on the Horizon: 19:20–22:24
Learn about ADCs designed to target TROP2 and EGFR that have shown promising results for people living with lung cancer.
ADC Side Effects: 22:25–25:11
Here you can learn more about the side effects that are commonly seen in patients being treated with ADCs.
Future of ADCs: 25:12–29:24
Travel with Dr. Levy into the future as he predicts the evolution of lung cancer treatments over the next five years. These are exciting times!
Wrap-Up: 29:25–33:53
Listen to Dr. Levy’s closing remarks and learn about the importance of patient-centered care and shared-decision making.
Audience Q&A: 33:54–51:11
Dr. Moore and Dr. Levy cover some of the most frequently asked questions about ADCs and answer more questions from the audience.
To learn more about treatment options for your specific type of lung cancer, visit the LUNGevity Patient Gateways.